Efficacy and Safety of Direct Oral Anticoagulants in Patients with Diabetes and Nonvalvular Atrial Fibrillation: Meta-Analysis of Observational Studies

<div>Forest plot comparing DOACs vs. VKAs regarding MACE in real-world NVAF patients with diabetes. MACE: major adverse cardiac events; NVAF: nonvalvular atrial fibrillation; DOACs: direct oral anticoagulants; VKAs: vitamin K antagonists; API: apixaban; DAB: dabigatran; EDO: edoxaban; RIV: rivaroxaban.</div>

Cardiovascular Therapeutics

fig3

Figure 3

Figure 3: Efficacy and Safety of Direct Oral Anticoagulants in Patients with Diabetes and Nonvalvular Atrial Fibrillation: Meta-Analysis of Observational Studies 

Figure 3 | Efficacy and Safety of Direct Oral Anticoagulants in Patients with Diabetes and Nonvalvular Atrial Fibrillation: Meta-Analysis of Observational Studies 